 SARASOTA, Fla., May 11, 2021 PRNewswire -- INVO Bioscience, Inc. NASDAQ: INVO, a medical device company focused on commercializing the worlds only in vivo Intravaginal Culture System IVC, INVOcell, an effective and affordable treatment for patients diagnosed with infertility, will report financial results for its first quarter 2021, ended March 31, 2021, after the market close on Monday, May 17, 2021. 